ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,067.00
-1.24%
S&P ASX All Technology
3,766.30
-0.74%
Brent Oil
72.72
0.00%
US Dollar vs AUD
1.59949
0.00%
Bitcoin
97,339.74
-0.43%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Atea Pharmaceuticals Inc (AVIR) Share Price

Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc (AVIR)

NASDAQ
3.19
0.06
(1.92%)
Closed 22 December 8:00AM
Delayed by 15 minutes
3.19
-0.02
(-0.62%)
After Hours: 10:56AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
3.19
Bid
3.19
Offer
3.94
Volume
1,242,722
3.11 Day's Range 3.315
2.30 52 Week Range 4.60
Market Cap
269.437M
Previous Close
3.13
Open
3.12
Last Trade
3305
@
3.19
(priorref)
Last Trade Time
Financial Volume
US$ 4,042,553
VWAP
3.253
Average Volume (3m)
250,430
Shares Outstanding
84,463,059
Dividend Yield
-
PE Ratio
-1.99
Earnings Per Share (EPS)
-1.61
Revenue
-
Net Profit
-135.96M

About Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treat... Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.ateapharma.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Atea Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AVIR. The last closing price for Atea Pharmaceuticals was US$3.13. Over the last year, Atea Pharmaceuticals shares have traded in a share price range of US$ 2.30 to US$ 4.60.

Atea Pharmaceuticals currently has 84,463,059 shares in issue. The market capitalisation of Atea Pharmaceuticals is US$264.37 million. Atea Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.99.

Ask ADVFN Intelligence (AI)

AVIR Latest News

More News

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...

16 December 2024
GlobeNewswire Inc.

Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) after Short Eight Week Treatment Duration Regimen Was Generally Safe and Well-Tolerated Global...

04 December 2024
GlobeNewswire Inc.

Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...

26 November 2024
GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness

20 November 2024
Edgar (US Regulatory)

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...

16 November 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

08 November 2024
Edgar (US Regulatory)

Form 8-K - Current report

08 November 2024
Edgar (US Regulatory)

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4’24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of...

08 November 2024
GlobeNewswire Inc.

Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...

31 October 2024
GlobeNewswire Inc.

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...

30 October 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.29102.93.272.8758324443.11366109CS
4-0.07-2.14723926383.263.542.754457463.10419884CS
12-0.3-8.595988538683.493.862.752504303.23548323CS
26-0.27-7.803468208093.464.1452.32438483.43801458CS
520.13.236245954693.094.62.33049453.67461163CS
156-5.36-62.69005847958.559.792.35065945.15997655CS
2602.3675287.8419452890.822594.17370.822583992915.00894585CS

AVIR - Frequently Asked Questions (FAQ)

What is the current Atea Pharmaceuticals share price?
The current share price of Atea Pharmaceuticals is US$ 3.19
How many Atea Pharmaceuticals shares are in issue?
Atea Pharmaceuticals has 84,463,059 shares in issue
What is the market cap of Atea Pharmaceuticals?
The market capitalisation of Atea Pharmaceuticals is USD 264.37M
What is the 1 year trading range for Atea Pharmaceuticals share price?
Atea Pharmaceuticals has traded in the range of US$ 2.30 to US$ 4.60 during the past year
What is the PE ratio of Atea Pharmaceuticals?
The price to earnings ratio of Atea Pharmaceuticals is -1.99
What is the reporting currency for Atea Pharmaceuticals?
Atea Pharmaceuticals reports financial results in USD
What is the latest annual profit for Atea Pharmaceuticals?
The latest annual profit of Atea Pharmaceuticals is USD -135.96M
What is the registered address of Atea Pharmaceuticals?
The registered address for Atea Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Atea Pharmaceuticals website address?
The website address for Atea Pharmaceuticals is www.ateapharma.com
Which industry sector does Atea Pharmaceuticals operate in?
Atea Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.91M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.75M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.94M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
9.27M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
6.25M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
281.23M

AVIR Discussion

View Posts
DewDiligence DewDiligence 3 months ago
AVIR phase-3 COVID trial fails—stock rises:

https://www.globenewswire.com/news-release/2024/09/13/2945844/0/en/Atea-Pharmaceuticals-Provides-Update-on-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Bemnifosbuvir-for-Treatment-of-COVID-19.html Atea Pharmaceuticals, Inc. (Nasdaq: AVIR)…today announced the outcome of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, versus placebo for the treatment of COVID-19. The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through Day 29 in the monotherapy cohort of 2,221 high-risk patients with mild to moderate COVID-19. This trial was a longshot insofar as Bemnifosbuvir is a repurposed HCV drug rather than something designed specifically for SARS-CoV-2. Moreover, the phase-2 trial for Bemnifosbuvir in COVID was unsuccessful, but AVIR plowed ahead anyhow.

I presume the share price is up slightly today because investors know that AVIR won’t waste more money pursuing COVID. AVIR had about $475M of net current assets as of 6/30/24.

AVIR’s CEO, Jean-Pierre Sommadossi, is continuing to pursue a treatment regimen for HCV, which is a rather extreme case of Zebra’s Law (#msg-172559198).
👍️0
Monksdream Monksdream 4 months ago
AVIR under $4
👍️0
DewDiligence DewDiligence 4 months ago
AVIR reports 2Q24 results—6/30/24 cash=$502.2M—down_from_$542M_at_3/31/24:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-second-quarter-200500091.html

CC slides:
https://ir.ateapharma.com/static-files/96ee237a-23d9-4515-8401-69794a5327e0
👍️0
DewDiligence DewDiligence 7 months ago
AVIR 1Q24 results:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-200500150.html

3/31/24 cash = $542M, down from $578M at 12/31/23.

Final results from the phase-3 SUNRISE COVID trial are expected in 2H24 (no change relative to the prior guidance). There are no interim analyses (#msg-174125019).
👍️0
Monksdream Monksdream 8 months ago
AVIR under $5
👍️0
DewDiligence DewDiligence 9 months ago
AVIR completes enrollment of phase-3 COVID trial—cancels interim analyses:

https://www.globenewswire.com/news-release/2024/03/27/2853010/0/en/Atea-Pharmaceuticals-Completes-Patient-Enrollment-in-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Oral-Antiviral-Bemnifosbuvir-for-COVID-19-in-High-Risk-Patients.html Atea Pharmaceuticals…today announced that the company has completed enrollment of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, or placebo for the treatment of COVID-19. Over 2,200 patients were randomized into the supportive care monotherapy cohort… The primary endpoint of the trial is all-cause hospitalization or death through Day 29 post-treatment in the bemnifosbuvir supportive care monotherapy cohort of high-risk patients. The two planned interim analyses have been canceled: “Since full enrollment was achieved ahead of the two planned interim analyses for safety and futility by the Data Safety Monitoring Board (DSMB), the analyses are no longer relevant, and in agreement with the DSMB, we will proceed to the full analysis of the trial. We look forward to reporting SUNRISE-3 results in the second half of 2024…
👍️0
DewDiligence DewDiligence 10 months ago
AVIR phase-3 COVID update:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-fourth-quarter-210500983.html

The first and second interim analyses in the phase-3 COVID trial will be performed in March and in 2Q24, respectively, and the final results will be available in 2H24. 1,400 patients have been enrolled in the bemnifosbuvir monotherapy cohort (the cohort that the primary endpoint is based on).

AVIR had $578M of cash at 12/31/23, which is why they can afford to blow so much money on a longshot trial.
👍️0
DewDiligence DewDiligence 2 years ago
AVIR rejects Tang buyout offer, as expected:

https://www.globenewswire.com/news-release/2023/05/30/2678205/0/en/Atea-Pharmaceuticals%5B%E2%80%A6%5DTang-Capital-Partners-Affiliate-Concentra-Biosciences.html

The offer was for less than AVIR’s cash value.
👍️0
DewDiligence DewDiligence 2 years ago
It's not a serious offering for the reason mentioned in #msg-171974875.
👍️0
mwn mwn 2 years ago
Why is the sp going so far below the offering?
👍️0
DewDiligence DewDiligence 2 years ago
Yes.
👍️0
Paullee Paullee 2 years ago
Did you not notice that a CVR of 80% is included in the package?
👍️0
DewDiligence DewDiligence 2 years ago
In other words, AVIR could do better than $5.75/sh by simply liquidating.
👍️0
DewDiligence DewDiligence 2 years ago
AVIR acknowledges Tang buyout offer—makes_no_recommendation_to_shareholders—(yet):

https://www.globenewswire.com/news-release/2023/05/23/2674788/0/en/Atea-Pharmaceuticals-Confirms-Receipt-of-Unsolicited-Proposal-from-Tang-Capital-Partners-Affiliate-Concentra-Biosciences.html

Even thought Tang’s $5.75/sh offer is a big premium to where AVIR was trading prior to the offer, it’s less than AVIR’s cash value per share. Hence, it’s hard to see how AVIR’s BoD could accept the offer. They could make a counter-proposal, of course.
👍️0
DewDiligence DewDiligence 2 years ago
Tang Capital makes_unsolicited AVIR buyout offer@$5.75/sh +CVR—a_55%_premium_to_Friday’s_close:

https://www.sec.gov/Archives/edgar/data/1593899/000121465923007616/z519230sc13d.htm (scan to bottom)

Why does Tang want to acquire AVIR? Presumably for AVIR’s COVID drug, AT-527, such as it is. AT-527 is a polymerase inhibitor that is similar to an HCV drug BMY dropped several years ago due to toxicity. AVIR is conducting a phase-3 trial in high-risk COVID patients using a daily dose of 1100 mg (550mg BID); the trial listing is at: https://www.clinicaltrials.gov/ct2/show/NCT05629962 .
👍️0
Awl416 Awl416 2 years ago
Volume
👍️0
DewDiligence DewDiligence 2 years ago
AVIR 1Q23 CC transcript:

https://finance.yahoo.com/news/q1-2023-atea-pharmaceuticals-inc-140930636.html
👍️0
DewDiligence DewDiligence 2 years ago
AVIR 1Q23 results:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-200500951.html

3/31/23 cash = $621M.
👍️0
V63 V63 2 years ago
So AVIR beat its earnings, and now it might bump up a little tomorrow.
👍️0
DewDiligence DewDiligence 2 years ago
AVIR reports final data from phase-2 COVID trial:

https://www.globenewswire.com/news-release/2023/04/12/2645185/0/en/Atea-Announces-Presentation-of-Bemnifosbuvir-Data-Demonstrating-Reduced-Hospitalizations-for-COVID-19-Patients-at-2023-European-Congress-of-Clinical-Microbiology-Infectious-Disease.html
👍️0
DewDiligence DewDiligence 2 years ago
AVIR 4Q22 CC transcript:

https://finance.yahoo.com/news/atea-pharmaceuticals-inc-nasdaq-avir-022000995.html
👍️0
DewDiligence DewDiligence 2 years ago
AVIR 4Q22 results—12/31/22 cash=$647M:

https://www.globenewswire.com/news-release/2023/02/28/2617674/0/en/Atea-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html

AVIR expects the interim analysis of the SUNRISE-3 (COVID) phase-3 trial to occur in 2H23. One possible outcome of the interim analysis is increasing the number of patients to provide more statistical power for the final analysis.
👍️0
DewDiligence DewDiligence 2 years ago
AVIR JPM webcast slides:

https://ir.ateapharma.com/static-files/731c461d-37e4-4364-8a12-eb605580b0aa
👍️0
DewDiligence DewDiligence 2 years ago
AVIR 2023 newsflow:

https://finance.yahoo.com/news/atea-pharmaceuticals-highlights-strategic-priorities-120000077.html
👍️0
DewDiligence DewDiligence 2 years ago
AVIR 3Q22 results—9/30/22 cash=$665M:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-third-quarter-210500282.html

A phase-3 trial of Bemnifosbuvir (f/k/a AT-527) in 1,500 high-risk, non-hospitalized COVID patients is expected to start by the end of 2022. AVIR is defining “high-risk” as: a) age 80+; b) age 65+ with 1 or more major risk factors; or c) an immunocompromised adult of any age.

The daily dose of Bemnifosbuvir is a whopping 1100mg (550mg BID).
👍️0
DewDiligence DewDiligence 2 years ago
AVIR 2Q22 results—6/30/22_cash=$684.5M (down from $705.5M at 3/31/22):

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-second-quarter-200500782.html
👍️0
DewDiligence DewDiligence 3 years ago
AVIR 3/31/22 cash=$705.5M—burning $58.9M in 1Q22...

1Q22 PR:
https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-103000747.html

1Q22 CC slides:
https://ir.ateapharma.com/static-files/8a966559-367b-4a3b-96c0-ff21958c0562
👍️0
DewDiligence DewDiligence 3 years ago
LOL re AVIR’s attempt to be relevant:

https://www.globenewswire.com/news-release/2021/12/14/2352116/0/en/Atea-Pharmaceuticals-Introduces-New-Strategic-Clinical-Development-Program-for-AT-527-in-COVID-19.html
👍️0
Jake L Jake L 3 years ago
AVIR - Friday Rundown, Monday Expectations

👍️0
Wallst_junkie Wallst_junkie 3 years ago
Watching for a uptrend
👍️0
dealerschool2006 dealerschool2006 3 years ago
GOOD JOB!!! ya, by the time I discovered AVIR it had gone up 50% from the bottom...
👍️0
crudeoil24 crudeoil24 3 years ago
Wow! That's why you don't hold these Pharma overnight.

AVIR
👍️0
TheFinalCD TheFinalCD 3 years ago
wow went sub $11 and traded the whole float, shit it traded the whole OS 1.5x today https://finviz.com/quote.ashx?t=AVIR
👍️0
DewDiligence DewDiligence 3 years ago
Why AVIR's AT-527 program is no-go: #msg-166425975.
👍️0
XWAVXALMIMAN XWAVXALMIMAN 3 years ago
David v Goliath

Interesting article - check out RDHL

https://www.yahoo.com/entertainment/david-v-goliath-race-develop-123328764.html
👍️0
Chess Master Chess Master 3 years ago
What a drop
👍️0
ecommceo ecommceo 3 years ago
Way over sold here.
👍️0
Planopenny Planopenny 3 years ago
Out at $16, easy $$$
👍️0
Docstemcell2020 Docstemcell2020 3 years ago
Let's go Brandon! FJB :)
👍️0
DewDiligence DewDiligence 3 years ago
AVIR CC slides (largely BS, IMO):

https://ir.ateapharma.com/static-files/d72bd065-82b3-4eeb-ad3a-40c5518d66d6
👍️0
Planopenny Planopenny 3 years ago
In at $10
👍️0
rosemountbomber rosemountbomber 3 years ago
Well the shit just hit the fan. Didn’t meet primary in study. Stock dow $28
👍️0
rosemountbomber rosemountbomber 3 years ago
Thanks DD
👍️0
DewDiligence DewDiligence 3 years ago
The primary endpoint in MRK’s molnupiravir trial was the proportion of patients, relative to placebo, who died or needed hospitalization within 28 days:

https://clinicaltrials.gov/ct2/show/NCT04575597
👍️0
rosemountbomber rosemountbomber 3 years ago
So I have to confess to my ignorance when it comes to anti-viral clinical trials. It appears that the primary outcome studied in the AT-527 phase 3 trial is evaluated using a Covid 19 Symptom Diary. It does not sound like it is something very precise when asking a patient to score themselves on these 12 questions (which I have not exactly found yet).

But my question is, did the Merck drug molnupiravir get tested using this same method (symptom diary)? It must have been more than that at least as they also measure deaths, etc. - although that may have been secondary outcomes.
👍️0
Whalatane Whalatane 3 years ago
AVIR presentation tomorrow Oct 5th

https://newsfilter.io/articles/atea-pharmaceuticals-to-present-at-guggenheim-2nd-annual-vaccines--infectious-day-conference-42a958b2016103f267b2f6525ac4ac0c

Kiwi
👍️0
crudeoil24 crudeoil24 3 years ago
You bet! > AVIR up 45% @ 50.05
👍️0
Whalatane Whalatane 3 years ago
Thx for the updates

Kiwi
👍️0
crudeoil24 crudeoil24 3 years ago
AVIR up 45% @ 50.05 > premarket.
👍️0
crudeoil24 crudeoil24 3 years ago
AVIR > 53M share trading float.
👍️0

Your Recent History

NASDAQ
AVIR
Atea Pharmaceuticals
LSE
97PZ
Res.mort.10'b'a
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads